Moderna Inc (NASDAQ:MRNA) has a beta value of 1.86 and has seen 1.86 million shares traded in the recent trading session. The company, currently valued at $10.35B, closed the recent trade at $26.75 per share which meant it gained $1.08 on the day or 4.23%% during that session. The MRNA stock price is -416.15% off its 52-week high price of $138.07 and 13.46% above the 52-week low of $23.15. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.88 million shares traded. The 3-month trading volume is 10.90 million shares.
The consensus among analysts is that Moderna Inc (MRNA) is Buy stock at the moment, with a recommendation rating of 2.86. 2 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 17 have rated it as a Hold, with 12 advising it as a Buy. 0 have rated the stock as Underweight.
Moderna Inc (NASDAQ:MRNA) trade information
Sporting 4.23%% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MRNA stock price touched $26.75 or saw a fall of -0.07%. Year-to-date, Moderna Inc shares have moved -80.09%, while the 5-day performance has seen it change 2.90%. Over the past 30 days, the shares of Moderna Inc (NASDAQ:MRNA) have changed 0.13%. Short interest in the company has seen 65.86 million shares shorted with days to cover at 4.73.
Wall Street analysts have a consensus price target for the stock at $47.5, which means that the shares’ value could jump 43.68% from the levels at last check today.. The projected low price target is $45.0 while the price target rests at a high of $50.0. In that case, then, we find that the latest price level in today’s session is -86.92% off the targeted high while a plunge would see the stock gain -68.22% from the levels at last check today..
Moderna Inc (MRNA) estimates and forecasts
The company’s shares have lost -30.25% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -42.94% over the past 5 years. Earnings growth for 2025 is a modest -8.51% while over the next 5 years, the company’s earnings are expected to increase by 20.72%.
MRNA Dividends
Moderna Inc is expected to release its next earnings report on 2025-May-01 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Insiders own 7.28% of the company shares, while shares held by institutions stand at 73.73% with a share float percentage of 79.52%. Investors are also buoyed by the number of investors in a company, with Moderna Inc having a total of 1076.0 institutions that hold shares in the company. The top two institutional holders are BAILLIE GIFFORD & CO with over 43.45 million shares worth more than $5.16 billion. As of 2024-06-30, BAILLIE GIFFORD & CO held 11.3149% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 39.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.7 billion and represent 10.3028% of shares outstanding.
